Population pharmocokinetics of high dose methotrexote;Paramètres pharmacocinétiques de population du méthotrexate administré à haute dose : Application en pratique clinique de routine

Journal de Pharmacie Clinique

Volumn 15, Issue 1, 1996, Pages 34-40

  Ciccolini, J ^a   Monjanel Mouterde, S ^a   Catalin, J ^a   Favre, R ^a   Durand, A ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Bayesian estimation; Clearance; Methotrexate; Population pharmacokinetics

Indexed keywords

METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; PHARMACOKINETICS;

EID: 0029872587     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. APIS. La Pharmacocinétique de routine. Logiciel Médical. Copyright MIIPS [19-21, rue Brandis, 13005 Marseille, France)
2. Beal SL, Sheiner LB. Methodology of population pharmacokinetics. Drug Fate and Metabolism 1985 ; 5 : 135-84.
3. Bressolle F, Ray P, Jacquet JM, Bres J, Galtier M, Donadio D, Jourdan J, Rossi JF. Bayesian estimation of Doxorubicin parameters. Cancer Chemother Pharmacol 1991 ; (29) : 53-60.
4. Bruno R, Iliadis A, Favre R, Lena N, Imbert AM, Cano JP. Dosage predictions in high dose methotrexate infusion part 2 : bayesian estimation of methotrexate clearance. Cancer Drug Del 1985 ; 2 (4) : 277-83.
5. Evans WE. Alternative approaches for phase I studies of anticancer drugs : a role for therapeutic drug monitoring. Ther Drug Monit 1993 ; 15 : 492-7.
6. Favre R, Monjavel S, Alfonsi M, Pradoura JP, Bagarry-Liegey D, Clement S, Imbert AM, Lena N, Colonna D'lstria J, Cano JP, Carcassonne Y. High dose of methotrexate : a clinical and pharmacokirtetics evaluation. Cancer Chemother Pharmacol 1982 ; 9 : 156-60.
7. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity : correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer 1972 ; 8 : 409-14.
8. e Journées Méditerranéennes de pharmacocinétique. Intérêts et limites de la pharmacocinétique en Recherche et Développement. Cap d'Agde 1988 ; Sauramps Médical ; Montpellier : 118-27.
9. Iliadis A. Un logiciel pour la pharmacocinétique clinique J Pharm Clin 1985 ; 4 : 573-7.
10. Iliadis A, Bachir-Raho M, Bruno R, Favre R. Bayesian estimation and prediction of clearance in high dose methotrexate infusions. J Pharmacokinet Biopharma 1985 ; 13 : 101-15.
11. Iliadis A, Bruno R, Cano JP. Steady state dosage regimen calculation in linear pharmacokinetics. Int J Biomed Comput 1986; 18 : 167-70.
12. Jaffe N, Frei E. High dose methotrexate in osteogenic sarcoma : a 5 years experience. Cancer Treat Rep 1978 ; 62 : 259-64.
13. Jones RB, Myers CE, Collins JM, Hubbard SM, Ballow JE, Brennan MF, Dedrick RL, De Vita VT. High volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 1981 ; 41 : 55-9.
14. Kovacs GT, Paals CH, Somlo P, Schuler D Borsi JD. Proteinuria due to suboptimal hydratation with high dose methotrexate. Cancer Chemother Pharmacol 1993 ; 33 : 262-3
15. Lawrence JR, Steele WH, Stuart JFB, McNeil CA, McVie JG, Withing B. Dose dependant methotrexate elimination following bolus IV injection. Eur J Clin Pharmacol 1980 ; 17 : 371-4.
16. Leme PR, Creaven PJ, Allen LM. Kinetics model for disposition and metabolism of moderate and high dose methotrexate in man. Cancer Chemother Rep 1975 ; 59 : 811-7.
17. Najjar TAO, Fawaz IMAI. Pnarmacokinetics of methotrexate in children with acute lymphocytic leukemia. Chemotherapy 1993 ; 39 (4) : 242-7.
18. Ogawa T, Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Komidono S. Clinical and pathological evaluations of methoirexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers. Cancer Chemother Pharmacol 1992 ; 30 suppl : s66-s71.
19. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, Monjanel S, Favre R. Pharmacokinetics of high dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994 ; 33 : 420-4.
20. Reich SD, Bachur NR, Goebel RH. A pharmacokinetics model for high dose methotrexate infusions in man. J Pharmacokinet Biopharm 1977 ; 5 : 421-33.
21. Rosen G, Capparos B, Huvos A, Kosloff C, Niremberg A, Cacavio A, Marcove R, Lane J, Metha B, Urjan C. Preoperative chemotherapy for osteogenic sarcoma selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to pre-operative chemotherapy. Cancer 1982; 49 : 1221-30.
22. Sheiner LB, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 ; 503-12.
23. Schornagel JH, Mac Vie JG. The clinical pharmacology of methotrexate. Cancer Treat Rev 1983 ; 10 : 53-75.
24. TDX FLX. Assays Manual methotrexate R 101. Abbott Laboratories USA.
25. Uexi O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C, Tsukahara, Sugata T. Methotrexate, Vinblastine, Doxorubicine and Cisplatin for advanced urothelial cancer. Cancer Chemother Pharmacol 1992 ; 30 : 572-6.